FDA RMAT Designation: Why the Evidence Bar Isn’t Breakthrough Therapy’s

Sponsors that already hold a Breakthrough Therapy designation often draft an RMAT request the same way — and get denied for arguing the wrong thing. The 21st Century Cures Act added Regenerative Medicine Advanced Therapy designation to Section 506 of the FD&C Act in 2016, one subsection away from Breakthrough Therapy. The two designations share a section number and most of their benefits. They do not share an evidentiary standard.

The three-part test Section 506(g) actually sets

RMAT eligibility runs on three conditions. First, the product has to be a regenerative medicine therapy: a cell therapy, a therapeutic tissue-engineering product, a human cell and tissue product, or a combination product using one of those — with products regulated solely under Section 361 of the Public Health Service Act carved out. Second, it has to be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. Third, and this is where most drafting goes wrong, preliminary clinical evidence has to indicate the product's potential to address an unmet medical need for that disease or condition. Nothing in that third prong asks for a comparison to what is already available — a distinction that matters for a regenerative medicine regulatory strategy built around a crowded therapeutic area rather than an open one.

Where the evidence bar actually diverges from Breakthrough Therapy

Breakthrough Therapy designation, created by FDASIA in 2012 as FD&C Act §506(a), asks for preliminary clinical evidence that the drug may demonstrate substantial improvement over available therapies on a clinically significant endpoint. That is a comparative standard: the sponsor has to show the product looks better than something that already exists. RMAT's §506(g) standard does not carry that comparison. It asks whether the evidence indicates the product's potential to meet a need that current therapies leave unmet — a standard a sponsor in a disease area with no approved therapy at all can satisfy more directly than the Breakthrough comparison ever allows.

• Breakthrough Therapy. Preliminary clinical evidence must indicate substantial improvement over available therapies on a clinically significant endpoint — a relative standard measured against a comparator.
• RMAT. Preliminary clinical evidence must indicate the product's potential to address an unmet medical need — an absolute standard measured against the disease, not a competing product.
• Accepted evidence types. FDA's 2019 guidance takes a deliberately broad view for RMAT, naming well-designed retrospective studies and clinical case series compiled systematically by treating physicians as acceptable alongside traditional trial data.
• Product scope. RMAT's definition reaches further than many sponsors assume — FDA has said certain human gene therapies and xenogeneic cell products can also meet the §506(g) definition of a regenerative medicine therapy.

An RMAT request that argues the product is better than what exists is answering Breakthrough Therapy's question. The request FDA is actually evaluating asks whether the disease has an answer at all. Why the framing matters at the request stage

What RMAT adds once it's granted

RMAT carries every benefit of Breakthrough Therapy and Fast Track: early and frequent interaction with FDA beginning as early as Phase 1, involvement of senior agency staff, and eligibility for rolling review of the marketing application. It adds two things Breakthrough Therapy does not provide on its own. A product with RMAT designation may be eligible for priority review if the application is supported by clinical data at the time of submission. And the statute directs FDA to work with the sponsor on ways to support approval through the accelerated approval pathway and the confirmatory trial clock it starts — including, where scientifically appropriate, satisfying postapproval requirements through real-world evidence such as patient registries or other observational data sources, rather than a conventional confirmatory trial alone. That last piece is a statutory direction to consider the option, not a guarantee FDA will accept a given RWE plan; it has to be negotiated on the specific evidence available, and it sits alongside — not instead of — the accelerated approval framework's ordinary requirements.

None of this is a reason to treat RMAT as easier to obtain than Breakthrough Therapy — it is a reason to treat it as a different question. Programs that build their cell and gene therapy quality and regulatory case around the unmet-need standard the statute actually sets, rather than recycling a Breakthrough Therapy narrative, are the ones that get a designation decision that matches the argument they made. For sponsors weighing RMAT against the rest of the FDA and EMA expedited pathway landscape — including how it interacts with orphan drug exclusivity strategy for the same product — the designation choice belongs in the development plan well before the pre-IND meeting, not after the data are already collected.